Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShanshan PeiWZWeiyan ZhengYZYi Zhao

Discussion

Loading...

Member takes

Overview

Real-world analysis shows a novel prognostic model for AML enhances survival predictions, indicating better treatment strategies with venetoclax and chemotherapy.

Key Points

  • The ICV-CHN model offers improved survival predictions for acute myeloid leukemia patients receiving venetoclax-based therapy.
  • Analysis revealed the model significantly distinguishes survival outcomes, with favorable-risk groups showing 91.4% OS at two years.
  • Using a random survival forest algorithm, the model identified critical fusion genes and mutations linked to prognosis.
  • The findings suggest an upgrade to existing risk classification systems to better inform treatment approaches in real-world settings.

Cite This Study

Pei et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da60https://doi.org/10.1182/blood-2025-3404
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model2025
  2. 2Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax2025
  3. 3Genetic risk model to predict outcomes for AML treated with HMA and venetoclax2025
  4. 4Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  5. 5Risk stratification of newly diagnosed AML receiving nonintensive treatment2025